InvestorLens

BMY — BRISTOL-MYERS SQUIBB CO

Health Care · Drug Manufacturers

Sign in to save5 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying BMY?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
80
Institutional Conviction
Net accumulation · 4 buying vs 1 selling last quarter
66
Macro Tailwind
Macro conditions are mixed for this sector
55
Congressional Activity
1 congressional purchase, 0 sales disclosed in the last 6 months
Why? — Evidence & Confidence ▾

Of 5 tracked investors who changed their BMY position last quarter, 4 bought and 1 sold (80% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 55/100 in a Squeeze regime). 1 congressional purchase, 0 sales disclosed in the last 6 months.

Supporting evidence
  • +4 tracked investors added or increased positions last quarter (Paul Tudor Jones, Izzy Englander, Ken Griffin, …)
  • +5 tracked investors reported holding BMY at their latest filing
  • +Macro Health is 52/100 in a Squeeze regime — historically acceptable for Health Caresource
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (1 reduced, 0 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/4/2026.

About BRISTOL-MYERS SQUIBB CO (BMY)

BRISTOL-MYERS SQUIBB CO (BMY) appears in the most recent 13F filings of 5 tracked institutional investors. BRISTOL-MYERS SQUIBB CO is classified in the Health Care sector (Drug Manufacturers industry). The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $578M. Across recent filings, tracked investors recorded 10 new positions, 0 increased, 2 reduced, and 0 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in BMY

83
/100
Strong Institutional Accumulation
Added / Increased10
Reduced2
Exited0
BearishBullish
Crowded Trade Score™

How many top investors track BMY

33
/100
Emerging Interest
5investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

BMY Ownership Composition

How BRISTOL-MYERS SQUIBB CO is held across tracked investor types, based on reported 13F positions.

Dominant Type
Other
94% of tracked value
Institutions
5
tracked investors
Total Reported
$1.1B
combined 13F value
Sectors2
  • Other94.0%
  • Hedge Funds6.0%
Other(4)
94.0%
Hedge Funds(1)
6.0%

Tracked investors reporting BMY

  • Ken GriffinMar 31, 2026
    Citadel Advisors
    Shares
    9.5M
    Value
    $578M
    % Portfolio
    0.09%
  • Izzy EnglanderMar 31, 2026
    Millennium Management
    Shares
    7.4M
    Value
    $446.1M
    % Portfolio
    0.19%
  • Steve CohenMar 31, 2026
    Point72 Asset Management
    Shares
    1.1M
    Value
    $66.7M
    % Portfolio
    0.09%
  • Ray DalioMar 31, 2026
    Bridgewater Associates
    Shares
    241.7K
    Value
    $14.7M
    % Portfolio
    0.07%
  • Paul Tudor JonesMar 31, 2026
    Tudor Investment Corp
    Shares
    257.1K
    Value
    $15.6M
    % Portfolio
    0.03%

Recent activity

Frequently asked questions

How many institutional investors hold BMY?
5 tracked institutional investors disclosed a position in BMY (BRISTOL-MYERS SQUIBB CO) in their most recent 13F filing.
Who is the largest institutional holder of BMY?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in BMY, valued at $578M.
Did institutional ownership of BMY increase or decrease?
Across recent 13F filings, tracked investors recorded 10 new positions, 0 increased, 2 reduced, and 0 fully exited BMY.
What sector is BMY in?
BRISTOL-MYERS SQUIBB CO is classified in the Health Care GICS sector, Drug Manufacturers industry.
Where does this BMY ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.
BMY (BRISTOL-MYERS SQUIBB CO) — Institutional Holders & 13F — InvestorLens